ScarDx wins Give Back grant to bring AI kidney-scarring scans to clinics
What's the deal? ScarDxDealroom has a profile for this one. Try Dealroom →, a newly formed Ontario health technology company, has secured a grant from Give Back Health Innovation FoundationDealroom has a profile for this one. Try Dealroom → to advance its non-invasive method of measuring kidney scarring, or fibrosis. The Canadian philanthropic network announced the partnership on October 6, 2026.
What's the endgame? ScarDx uses AI to analyze data from standard ultrasound images, aiming to give clinicians visibility into kidney scarring without invasive biopsies. The technology emerged from research at the Keenan Research Centre for Biomedical Science at St. Michael's HospitalDealroom has a profile for this one. Try Dealroom →, part of Unity Health TorontoDealroom has a profile for this one. Try Dealroom →.
Why now? Kidney disease affects roughly one in 10 people in Canada and worldwide, creating demand for more accessible diagnostic tools. The research won the Keenan Award for Medical Discovery in 2024, and the grant now moves it toward commercialization.
Give Back provides philanthropic capital through a model that, in its words, "puts health outcomes ahead of financial returns." The not-for-profit connects donor contributions with Canadian health ventures to help them reach scale.
What they're saying: "Doctors have limited ways to safely see the extent of kidney scarring and our goal is to close that diagnostic blind spot," said co-founders Darren Yuen, a nephrologist, and Eno Hysi, a physicist, both at St. Michael's Hospital.
The signal: The grant reflects a push to translate Ontario research into scalable health technology, backed by philanthropic rather than venture capital. For ScarDx, it is a step from the lab toward clinical use — and a test of whether a donor-funded model can carry Canadian discoveries to market.
Read more: finance.yahoo.com
Image credit: Generated with Gemini
